Xin Lang Zheng Quan·2025-10-21 03:20Core Viewpoint - The stock price of Haiprui has shown fluctuations, with a year-to-date increase of 14.27% and a recent decline over the past 20 and 60 days, indicating volatility in its market performance [2]. Company Overview - Haiprui Pharmaceutical Group Co., Ltd. is located in Nanshan District, Shenzhen, Guangdong Province, and was established on April 21, 1998. The company was listed on May 6, 2010 [2]. - The main business involves the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products. The revenue composition is as follows: formulations 63.06%, CDMO 18.59%, heparin sodium and low molecular weight heparin raw materials 16.05%, and others 2.30% [2]. Financial Performance - For the first half of 2025, Haiprui achieved operating revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%. The net profit attributable to the parent company was 422 million yuan, down 36.44% year-on-year [2]. - Since its A-share listing, Haiprui has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Haiprui was 26,300, a decrease of 7.29% from the previous period. The average circulating shares per person remained at 0 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the eighth largest, holding 11.3176 million shares, an increase of 6.3765 million shares from the previous period [3].